ОГЛЯД СУЧАСНИХ ПЕРОРАЛЬНИХ ФОРМ ІНСУЛІНУ
Ключові слова:
oral insulin, diabetes mellitus, nanocarriers, microrobots.Анотація
This study evaluates oral insulin as a physiological alternative to injections. Overcoming GI barriers via nanoparticles and microrobots shows preclinical promise. However, clinical candidates face variability and scalability issues. Success depends on integrating advanced nanomedicine to bridge the translational gap.
Посилання
E. Zhang et al. Recent advances in oral insulin delivery technologies. Journal of Controlled Release. 2024. Т. 366. С. 221–230. URL: https://doi.org/10.1016/j.jconrel.2023.12.045.
Zheng Y., Fang X., Gao J. Re-engineering insulin for oral delivery: structural modifications, advanced formulation strategies, and future directions. Drug Delivery. 2026. Т. 33, № 1. URL: https://doi.org/10.1080/10717544.2026.2624192.
H.-W. Sung et al. pH-Responsive Nanoparticles Shelled with Chitosan for Oral Delivery of Insulin: From Mechanism to Therapeutic Applications. Accounts of Chemical Research. 2012. Т. 45, № 4. С. 619–629. URL: https://doi.org/10.1021/ar200234q.
H. Wu et al. Insulin-loaded liposomes packaged in alginate hydrogels promote the oral bioavailability of insulin. Journal of Controlled Release. 2023. Т. 353. С. 51–62. URL: https://doi.org/10.1016/j.jconrel.2022.11.032.
M.-C. Chen et al. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials. 2011. Т. 32, № 36. С. 9826–9838. URL: https://doi.org/10.1016/j.biomaterials.2011.08.087.
Poudwal S., Misra A., Shende P. Role of lipid nanocarriers for enhancing oral absorption and bioavailability of insulin and GLP-1 receptor agonists. Journal of Drug Targeting. 2021. Т. 29, № 8. С. 834–847. URL: https://doi.org/10.1080/1061186x.2021.1894434.
A. Abramson et al. Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors. Nature Biotechnology. 2021. URL: https://doi.org/10.1038/s41587-021-01024-0.
E. Latres et al. An open‐label, multiple ascending dose trial of orally administered insulin Tregopil in patients with type 1 diabetes mellitus to evaluate its pharmacokinetics, pharmacodynamics, safety and tolerability . Diabetes, Obesity and Metabolism. 2025. URL: https://doi.org/10.1111/dom.16327.
A. Khedkar et al. Pharmacokinetics and Pharmacodynamics of Insulin Tregopil in Relation to Premeal Dosing Time, Between Meal Interval, and Meal Composition in Patients With Type 2 Diabetes Mellitus. Clinical Pharmacology in Drug Development. 2019. Т. 9, № 1. С. 74–86. URL: https://doi.org/10.1002/cpdd.730.
